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ABSTRACT

Inflammation has long been associated with tumorigenesis. Macrophages are cells of the
innate immune system, whose density within tumors correlates with a worsening clinical
prognosis in most types of tumors. Macrophages have been demonstrated to contribute to
the initiation, growth, invasion, and metastasis of tumors. We hypothesized that
macrophage density and phenotype differs between squamous cell carcinomas and basal
cell carcinomas, two skin cancers with relatively aggressive and indolent clinical
behaviors, respectively. Through immunohistochemical analysis, we determined that
squamous cell carcinomas have a 5-fold higher density of macrophages than basal cell
carcinomas. Tumor-associated macrophages exhibit two classic states of activation. M1
macrophages are inflammatory and are involved in clearance of microorganisms and
tumor cells. By contrast, M2 macrophages are involved in tissue remodeling,
angiogenesis, and are tumor-promoting. Using flow cytometric analysis of fresh clinical
specimens, we determined that macrophages from squamous cell carcinomas express
significantly higher levels of M1 (CD40, CD127) and M2 (arginase I) markers as well as
higher levels of MMP-9, a pivotal enzyme in tumor matrix remodeling and tumor
invasion, than macrophages from the basal cell carcinomas. To determine whether the
Toll-like receptor (TLR) agonist imiquimod, an FDA-approved treatment for superficial
basal cell carcinoma and actinic keratoses, alters the activation state of tumor-associated
macrophages, we studied in vitro and in vivo effects of imiquimod on macrophages. We
determined that imiquimod activates primary macrophages from human squamous cell
carcinoma to an M1, pro-inflammatory immunophenotype. This phenotype was

	
  

	
  
associated with enhanced macrophage-induced apoptosis of cultured epidermoid
carcinoma cells and enhanced phagocytosis of fluorescently labeled tumor cells. Our
findings suggest that tumor-associated macrophages play a critical role in
pathophysiology of two common human skin cancers. Further, we provide a novel
mechanism of action of imiquimod, which provides potential insights in the utilization of
immunomodulatory therapies in the treatments of a wider variety of cancers.
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INTRODUCTION
Inflammation is recognized as being important for tumorigenesis and was recently
proposed as the seventh hallmark of cancer (1-3). The inflammatory infiltrate in tumors
most commonly consists predominantly of macrophages, T cells, neutrophils, natural
killer (NK) cells – but includes other hematopoietic cells (4). Among these cells,
macrophages are the most numerous cells in this tumor infiltrate (5). Tumor-associated
macrophages (TAMs) are closely involved in multiple stages of carcinogenesis: they
contribute to initiation, growth, invasion, and metastasis of tumors through production of
a diverse array of cytokines, growth factors, pro-angiogenic factors, and matrix
metalloproteinases (6-8).
The most common cancer in the United States is non-melanoma skin cancer with
an estimated 1.3 million cases each year (9). The incidence of NMSC is increasing
worldwide (10-12). It is essential to understand macrophage phenotypic characteristics in
tumors of diverse clinical behavior to understand which factors correlate with tumor
growth, invasion and metastasis. The two most common forms of NMSC are basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC) (13). BCC and SCC are ideal
tumors to consider in study of TAMs in humans as they represent two common epidermal
neoplasms that behave differently clinically. BCCs only grow and invade locally and do
not metastasize (14, 15). In contrast, SCCs are more invasive and can metastasize in late
stages (9). Sun exposure, specifically UV-B radiation, is considered to be one of the most
important environmental factors involved in initiation of SCC (9). UV-B exposure
directly leads to DNA and RNA damage through formation of pyrimidine dimers (13). A
limited number of studies have examined the role of macrophages in skin cancer. In
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BCC, it has been shown recently that the number of TAMs infiltrating the tumor directly
correlates with depth of tumor invasion and microvessel density (18). In cutaneous SCC,
TAMs are shown to be a major source of VEGF-C, a critical lymphangiogenic factor
(19). Therefore, study of in vivo TAMs in SCC and BCC represents a suitable strategy for
further understanding of cutaneous carcinogenesis.
TAMs classically exhibit two states of activation known as M1 and M2 states.
Macrophages are polarized in response to Th1 cytokines, LPS and IFN-gamma, into an
M1 state (2, 20, 21). On the other hand, in response to Th2 cytokines, IL-4 and IL-13,
macrophages enter an M2 state (2, 21). M1 macrophages are inflammatory and produce a
variety of pro-inflammatory factors such as IL-1β, TNF-α, and IL-6 (2, 21). In general,
M1 macrophages are involved in clearance of microorganisms. M2 macrophages on the
other hand are involved in type 2 inflammation, tissue remodeling, angiogenesis, and are
believed to promote tumor growth (2, 22, 23). M2 macrophages produce high levels of
Interleukin-10 (IL-10) and arginase I and express numerous scavenger receptors (2). The
classical M1-M2 paradigm has been recently revealed to represent two ends of a
spectrum that can also include heterogeneous states of activation. It has been shown in
multiple studies that macrophages can show mixed states of activation and there are
multiple sub-populations of TAMs (24, 25).
Imiquimod is a topically used imidazoquinoline drug approved by the Food and
Drug Administration (FDA) for treatment of superficial BCCs, Actinic Keratoses, and
warts (13). It is known to possess antiviral and anti-tumoral effects. Mechanistically,
imiquimod is an immune response modifier and can also lead to direct tumor cell death,
possibly by down-regulation of BCL-2 anti-apoptosis gene (26). Imiquimod has been
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shown to be a specific agonist of TLR-7 in macrophages, a major arm of the innate
immune system. Imiquimod and resiquimod (R848) activation of macrophages is
MyD88-dependent (27, 28). We sought to characterize how TAMs are modulated by
imiquimod both in vivo and in vitro. We utilized both imiquimod and resiquimod in our
experiments. We hypothesized that imiquimod will act as a modulator of TAM
phenotype towards a tumoricidal state and away from trophic, tumor-promoting
functions.
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STATEMENT OF PURPOSE & HYPOTHESIS

The specific aims and hypotheses of this thesis project are as follows:
1) Compare density of TAMs in human SCCs and BCCs:
Hypothesis: Given that increasing macrophage density typically correlates with
tumor aggressiveness, we hypothesize that there will be a higher density of TAMs
in SCCs as compared to BCCs.
2) Characterize in vivo M1-M2 immunophenotype of TAMs in SCC and BCC
tumors using flow cytometry and determine whether tumor-derived soluble
factor(s) are sufficient to reproduce this phenotype in vitro:
Hypothesis: TAMs have differential activation in SCCs and BCCs, which may
contribute to their distinct clinical behavior. Soluble factors derived from these
tumors can induce human macrophages to assume an immunophenotype similar
to the in vivo immunophenotype of TAMs in SCCs and BCCs.
3) Determine whether imiquimod can modulate TAM immunophenotype in vivo
and in vitro.
Hypothesis: Imiquimod can polarize macrophages towards an M1, proinflammatory state.
4) Determine whether imiquimod-primed macrophages can induce apoptosis of
tumor cells and enhance phagocytic capacity of macrophages for tumor cells
Hypothesis: Imiquimod can activate macrophages to induce apoptosis of
carcinoma cells. Furthermore, imiquimod can enhance phagocytosis of carcinoma
cells by macrophages.
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METHODS
All subjects participated voluntarily in this study after signing an informed consent.
Human Investigation Committee approval was obtained prior to start of research project.
Subjects were not exposed to any risks in this study as they were undergoing routine
cutaneous surgery for the excision of skin cancer and agreed to donate the specimen for
research. All experiments detailed in the subsequent sections were carried out by the
author in Yale Departments of Dermatology and Immunobiology except for
immunohistochemical staining of the SCC and BCC samples, which was performed by
the Yale Dermatopathology Lab. Tumor histology was evaluated by board-certified
dermatopathologists to ensure that tumors were either SCC or BCC prior to being
included in experiments.

I) Immunohistochemistry:

Biopsy-proven BCCs (n=6) and SCCs (n=5) were confirmed by a dermatopathologist and
utilized for immunohistochemical staining of TAMs. Tissue sections were stained with
hematoxylin and eosin and CD68 antibody by the Yale Dermatopathology Lab. CD68+
macrophages were visualized at 40X magnification with OTIPHON Nikon microscope.
Numbers of TAMs per 40X HPF were counted with ImageJ by two independent
researchers.
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II) Mechanical and enzymatic digestion of cutaneous tumors into single cell
suspensions:
Biopsy-proven cutaneous SCC and BCC extirpated by Mohs micrographic surgery were
used after obtaining informed consent. The debulked tumor specimens were transported
on ice. The tumors were weighed, and the length and width were measured to nearest
millimeter. Next, the tumor was minced using surgical scissors into small pieces, all less
than 2 mm in length. The digestion buffer consisting of Liberase TM at final
concentration of 26 Wünsch/mL and DNase in PBS with calcium and magnesium was
prepared. The specimen was then transferred to 10-20 mL of digestion buffer depending
on tumor weight in a 50 mL conical tube. The digestion was carried out in a shaking
incubator at 37 ºC for 90 minutes. After the end of the incubation period, 0.1 M
Ethylenediaminetetraacetic acid (EDTA) was added at dilution of 1:50 and the digest was
placed on ice for 5 minutes to stop the enzymatic reaction. In order to acquire a single
cell suspension, the tumor digest was passed through a custom metal sieve designed to
remove larger clumps of undigested matter. Next, the filtered liquid was passed through a
70 µm cell strainer. This resulted in a homogenous cell suspension that was subsequently
centrifuged at 1300 rpm for 5 min at 4 ºC. After centrifugation, the pellet was resuspended in ACK lysis buffer to lyse erythrocytes. The reaction was stopped with FACS
buffer (0.5 % fetal bovine serum in PBS), and after centrifugation the final purified cell
suspension was suspended in FACS buffer. Using trypan blue staining cell viability was
assessed and cell count was approximated.

III) Immunophenotyping of Macrophages in human SCCs and BCCs
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The final tumor digests were plated in a 96-well plate at 1-2 million cells / well consisting
of an unstained condition, and three separate panels designed to determine M1 and M2
activation states in tumor associated macrophages. Prior to staining macrophages, Fcblock was carried out by adding 50 µL of 1:200 diluted human Fc-Block solution
(eBioscience) and the sample was incubated for 20 minutes on ice, in the dark. The
sample was then washed with FACS buffer. The samples were then stained by adding 50
uL of surface antibodies CD127-PerCP-Cy5.5, CD40-PerCP-Cy5.5, CD45-APC, and
CD163-APC at recommended dilutions (eBioscience, Biolegend). The samples were
incubated for 15 minutes in dark on ice. 150 uL of FACS buffer was added to each
sample, followed by centrifugation at 1300 rpm for 5 minutes, and removal of
supernatant. The wash was repeated a second time.
Utilizing the standard protocol for intracellular staining from BD Biosciences, the
samples were processed. The intracellular stains CD68-PE (2.5 uL per million cells),
arginase I-CFS (10 µL per million cells, R&D systems) and MMP-9 CFS (10 µL per
million cells, R&D Systems) were added to each sample in a final volume of 50 µL per
well. The intracellular staining was carried out per manufacturer’s instructions (BD
biosciences). All FACS analysis was carried out either immediately or within 12 hours
with sample stored in dark and at 4 ºC. Single color controls were prepared utilizing BD
Compensation beads (positive and negative beads) and the same antibodies used at
identical dilutions per manufacturer’s instructions. All antibodies had Fc-gamma chains
that are appropriate for use with the Comp Beads. FACS analysis was carried out on BD
FACS Calibur. The PMT voltages were adjusted using the unstained sample containing
the purified tumor cell suspension processed identically as the stained samples while
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replacing the staining steps with buffers. After setting appropriate voltages and gating on
live cells based on Forward Scatter (FSC) and Side Scatter (SSC), the compensation was
carried out with Comp Beads. Next, samples were analyzed with the BD FACS Calibur
flow cytometer. To achieve statistical significance, 100,000-1 million events were
collected for each sample. The acquired data was analyzed using FlowJo. The
preparation techniques, staining procedures, and antibody dilutions, and data analyses
were identical for both BCCs and SCCs allowing direct comparison of FACS data.

IV) Stimulation of THP-1 cells (human monocytic cell line) with tumor-conditioned
media
Tumor-conditioned media was prepared by manual mincing of SCC and BCC specimens
with surgical scissors and re-suspending in complete RPMI media. The tumor-media
suspension was incubated at 37 ºC in a humidified tissue culture (TC) incubator. The
tumor supernatant was then carefully aspirated, centrifuged, and sterile filtered with 0.45
µm syringe filter. The tumor-conditioned media were stored at -80°C for future
experiments. For in vitro, stimulation of THP-1 cells (human monocytic cell line), 1
million THP-1 cells were plated in 1 mL of tumor-conditioned media in sterile six-well
tissue culture plates and incubated for 48 hours. The THP-1 cells were then utilized for
flow cytometric immunophenotyping as previously described.

V) Co-culture of human SCC, peri-tumoral skin with THP-1 cells
For co-culture assay, fresh Mohs debulked SCC specimens and peri-tumoral normal skin
from the same patient were manually dissociated with surgical scissors and placed in
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complete media in the Transwell cell culture insert (1 µm) immediately after surgery. 1
million THP-1 cells were plated in 1 mL of complete RPMI in six-well plates. The coculture assay was carried out for 48 hours and 72 hours in 37°C humidified TC incubator.
A negative control with no co-culture was also included. At the end of incubation time,
the upper insert was removed, and THP-1 cells were washed and utilized for flow
cytometric immunophenotyping as described previously.

VI) In vitro study of imiquimod’s effect on THP-1 cells
THP-1 cells were plated in RMPI complete at density of 1 million/mL in sterile six-well
or twelve-well tissue culture plates. The control conditions included negative control
(plain RPMI complete), positive control (LPS 100 ng/mL, human IFN-gamma 20 ng/mL
in RPMI complete. For in vitro study of mechanism of imiquimod, THP-1 cells were
incubated in multi-well plates as follows: 1) Negative control. 2) Positive control 3) 50
µg/mL imiquimod (Invivogen) 4) 10 µg/mL resiquimod (Invivogen). THP-1 cells were
incubated for 48 hours in 37°C humidified TC incubator (5 % CO2). After 48 hours, cells
were harvested with cold PBS and processed for flow cytometry. Briefly, cells were Fcblocked and stained with CD40, CD127, arginase I, MMP-9, CD45, and CD68 as
described previously, and analyzed with BD FACS Calibur. Data was analyzed with
FlowJo: Live cells were gated upon based on FSC and SSC. CD68+CD45+ THP-1 cells
were next selected and histograms created for all the markers mentioned. For
investigation of imiquimod's effects on TAMs, THP-1 cells were plated in sterile 12-well
tissue culture plates with the following conditions included: BCC-conditioned media with
and without 50 µg/mL imiquimod, SCC-conditioned media with and without imiquimod
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50 µg/mL, and RPMI complete serving as negative control. After 48 hours of incubation
in humidified 37°C TC incubator, THP-1 cells were harvested, washed, and prepared for
FACS immunophenotype of M1, M2 and MMP-9 as previously described.

VII) In vivo immunophenotype of TAMs imiquimod-treated patient
For in vivo experiments, we obtained a fresh SCC debulk specimen in a patient treated
with 2.5 % imiquimod for two weeks prior to surgery. A comparable SCC in a patient not
treated with imiquimod was analyzed on the same day. We used the optimized enzymatic
dissociation protocol, previously described, to create single cell suspensions. Next, the
cell suspension was prepared for FACS immunophenotype and processed for both
imiquimod treated SCC and control SCC.

VIII) Apoptosis assay for evaluation of imiquimod-primed macrophages effect on
A431 carcinoma cells
THP-1 cells were stimulated with 50 µg/mL imiquimod in RPMI complete media. THP-1
cells in RPMI complete media were used as negative controls. THP-1 cells were
incubated for 48 hours in humidified TC incubator at 37°C. At the end of incubation, the
THP-1 cells’ suspension was centrifuged at 1300 RPM for 5 min, and the supernatant
was aspirated. Next, the pellet was re-suspended in 20 mL of cold PBS. The suspension
was re-centrifuged and all of the supernatant was carefully aspirated. The final THP-1
cell pellet was re-suspended in DMEM complete and placed on ice. A431 epidermoid
carcinoma cells were plated in sterile non-tissue culture six-well plate at density of 1
million per well in EMEM complete. Transwell cell culture insert (1 µm) were placed on
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top of each well using sterile forceps. 1 million THP-1 cells from control and imiquimod
pre-treated group were added to Transwell cell culture inserts in the six-well plate. The
THP1-A431 co-culture plate was then incubated in a humidified TC incubator at 37 ºC
for 72 hours. At the end of incubation, the upper cell culture insert containing THP-1
cells was carefully removed. A431 epidermoid carcinoma cells were gently trypsinized
off the wells and re-suspended in EMEM complete. Annexin V FITC apoptosis kit from
eBioscience was used for the measurement of rate of apoptosis per manufacturer’s
instructions. The tumor cells were first washed with cold PBS and then binding buffer.
The samples were re-suspended in 200 µL of binding buffer. Five µL of Annexin V FITC
was added to each well and mixed. The samples were then incubated for 10 minutes in
dark. After completion of staining, the samples were washed with 200 µL of binding
buffer. The samples were re-suspended in 200 µL of binding buffer and 5 µL of
propidium iodide staining solution (eBioscience) was added. The samples were analyzed
using FACS BD Calibur and compensations were carried out using unstained and BD
compensation beads. Annexin V staining was calculated using the FITC channel and
propidium iodide was measured in PerCP channel. Data was analyzed using FlowJo and
Prism. Rate of early apoptosis was calculated as percentage of FITC positive cells. Rate
of late apoptosis was calculated as percentage of FITC/PerCP double positive cells,
which stained for both Annexin V-FITC and propidium iodide.

IX) Phagocytosis assay for investigation of phagocytic capacity of imiquimodprimed macrophages
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THP-1 cells were stimulated using imiquimod 50 µg/mL in RPMI complete and
control RPMI complete as previously described for 48 hours in humidified 37 ºC TC
incubator. After end of incubation, the samples were centrifuged and the supernatants
were aspirated. Twenty mL of cold PBS was used to wash the THP-1 cells. After
centrifugation, all of the supernatant was carefully aspirated. The THP-1 cells were kept
on ice. A431 epidermoid carcinoma cells were then labeled with PE fluorescent dye using
PKH26 Red Fluorescent Cell Linker per manufacturer’s instructions (Sigma Aldrich).
Briefly, A431 cells were first washed with serum-free media, and then re-suspended in 1
mL of Diluent C. PKH26 dye solution was prepared in 1 mL of Diluent C by adding 4 uL
of PKH26 dye. The prepared dye solution was rapidly added to the cell suspension and
mixed thoroughly through pipetting up and down. The sample was then incubated for 2
minutes and serum was added to stop the reaction. The sample was then centrifuged at
400g for 10 minutes. The supernatant was aspirated and cells were suspended in 10 mL
of complete media and transferred to a new tube. The cells were washed an additional
two times with complete media prior to being used in experiments.
PE-labeled tumor cells were then used for the purpose of phagocytosis
experiments. One million THP-1 control cells were mixed with 6 million PE-labeled
epidermoid carcinoma cells in a 50 mL conical tube, which served as the control group.
One million THP-1 cells pre-treated with imiquimod were mixed with 6 million PElabeled epidermoid carcinoma cells, serving as the imiquimod group. Another condition
included only THP-1 control cells without PE-labeled tumor cells to serve as cell-free
control. The samples were then incubated in a shaking TC incubator for 60 minutes at
200 rotations per minute (RPM). After incubation, the samples were prepared for flow
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cytometry as previously described using CD45-APC stain. Briefly, the samples were resuspended in FACS buffer and were Fc-Blocked using human Fc Block (eBioscience).
Next, the samples were washed once with FACS buffer. CD45 APC was utilized to stain
the samples (5 uL per 1 million cells) for 15 minutes in dark on ice. Next, the samples
were washed with 200 uL of FACS buffer two times. The samples were analyzed on
FACS Calibur. Rate of phagocytosis was determined by first gating on THP-1 cells using
CD45-APC. After gating on macrophages, the percentage of PE-positive macrophages
was used as marker of phagocytosis.

X) Statistical analysis
FACS data were analyzed with FlowJo. All statistical tests were performed with Prism
utilizing unpaired, two-tailed Student’s t test.
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RESULTS
The characteristics of subjects in this study for Immunophenotyping of TAMs in NMSCs,
in vitro experiments, and imiquimod mechanistic experiments are shown in Table A.
Age, gender, diagnosis, duration of lesion, and history of recurrent skin cancer for each
patient are listed. Histopathologic diagnosis and features, tumor dimensions (mm), and
anatomic locations are also shown (Table A).

Human cutaneous SCCs have significantly higher density of TAMs compared to
BCCs.
In order to determine the density of TAMs in human cutaneous SCC, we stained H&E
slides of biopsy-proven SCCs and BCCs with CD68 and quantified number of TAMs per
high-power field (HPF). Analysis of SCCs (n=5) and BCCs (n=6) revealed that there is
significantly higher density of TAMs in SCC compared to BCC (Figure 1b, p value <
0.0001, unpaired two-tailed student t test). Representative histology of SCC and BCC are
shown in Figure 1a demonstrating the distinctly different density of CD68+ TAMs in
these two common forms of NMSC.

Development of a method to analyze TAMs from primary SCC and BCC tumors
Utilizing a combination of manual mechanical dissociation and enzymatic digestion with
Liberase (Roche), we obtained a viable suspension from human SCCs and BCCs from
multiple patients. All preparation was performed on the day of the Mohs micrographic
surgery on patients with biopsy-proven cutaneous carcinomas. To our knowledge this
represents the first successful FACS analysis of tumor associated macrophages in human
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cutaneous SCCs and BCCs. After optimization of the digestion process, we were able to
obtain 5-30 million total cells from each tumor depending on weight. After the digestion
process, cells were counted and trypan blue staining demonstrated that the cellular digest
consisted of viable cells. The human tumor digest was then prepared for flow cytometric
analysis of macrophages with multiple M1, M2, and TAM markers immediately after
digestion. All FACS staining was performed on freshly digested specimens. Our
immunophenotype panels were designed to characterize TAMs for their M1 and M2
polarization states. CD127 (IL-7 receptor) and CD40 (co-stimulatory receptor) were used
as M1 markers (2, 24, 29, 30). Arginase I (2, 24) was used as an M2 marker. The
advantage of FACS in comparison with immunohistochemistry is that multiple markers
can be studied simultaneously and in a way to recognize multiple sub-populations. Given
the recently recognized heterogeneity of TAM expression profile, FACS is an ideal
method to detect distinct sub-populations of TAMs and also detect simultaneous M1 and
M2 activation.
By FACS analysis, we gated on a clear CD68+ CD45+ TAM population from
both SCCs and BCCs. CD45 was utilized in addition to the classic macrophage maker
(CD68) to ensure that only leukocytes were included in the analysis and tumor cells are
excluded. First, we selected for live cells by gating on FSC and SSC. The plot of CD68PE versus CD45-APC demonstrates a clear double positive population that represents
TAMs in human BCC and SCC (Figure 2a). In addition to CD68, we also used CD163,
as another marker of TAMs in the skin. Percentage of C68+CD45+ TAMs in the tumor
digest was not significantly different between SCCs and BCCs (mean 2.7 % in SCC
versus 2.2 % in BCC. p > 0.05). This is in contrast to the findings from quantitative
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immunohistochemistry and may represent a limitation of isolating individual living cells
from tissue.

TAMs from SCCs and BCCs have different degrees of polarization.
Based on our analysis of published microarrays of NMSC, human cutaneous
SCCs and BCCs have distinct microarray gene profiles of CD68, MMP-9 and arginase I
(Figure 3). We analyzed published whole tumor microarrays of human SCCs (n=13) and
BCCs (n=11) and Normal skin (n=4) to investigate expression profiles of CD68, arginase
I, MMP-9 (31). Mean values of microarray signals for MMP-9, CD68, arginase I and
SEM were calculated. Percentage present (%) was defined as percentage of all samples
with significant p-values indicating that the gene is present in microarray profile of the
tumor. In these expression arrays, CD68 was more highly expressed in SCC compared to
BCC, and both skin cancers had higher CD68 expression than normal skin (Figure 3).
MMP-9 shows stronger expression in SCC as compared to BCC and normal skin (Figure
3). In addition, arginase I (probe 1) was present in significantly higher percentage of SCC
tumors as compared to BCC (Figure 3). In a similar fashion, arginase I (probe 2) was
present in 36% of SCC tumors yet completely absent from BCC and normal skin (Figure
3). The results of whole tumor microarray analysis showed that CD68 (macrophage
marker), arginase I (M2), and MMP-9 (TAM marker) had higher expression levels in
SCC as compared to BCC and normal skin control. The results of this whole tumor
microarray analysis suggested differential activation of TAMs in SCC versus BCC.
To address this question using FACS analysis, SCCs (n=7) and BCCs (n=7) were
processed for flow cytometric immunophenotyping of TAMs using an optimized method
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of enzymatic dissociation (Figure 2). We compared levels of arginase I and MMP-9 in
TAMs in SCC (CD68+CD45+) in comparison with other leukocytes (CD68-CD45+)
(Figure 2a-b). We observed significantly higher levels of both arginase I and MMP9 in
TAMs as compared to other WBCs (Figure 2b). In addition, TAMs had higher levels of
both arginase I and MMP-9 as compared to tumor cells (CD68-CD45-, data not
displayed).
Immunophentyping of TAMs in human NMSCs demonstrated that TAMs in
cutaneous SCC had significantly higher levels of MMP-9 compared to cutaneous BCC.
This was demonstrated by a reproducible shift in histograms of MMP9-CFS observed in
BCC and SCC (Figure 2c). In addition, intracellular human arginase I intracellular
staining revealed that TAMs in SCC expressed higher levels of arginase I compared to
TAMs in BCC (Figure 2c). This demonstrated that macrophages in SCC are M2
activated whereas macrophages in BCC have minimal M2 activation. In terms of
expression of M1 markers CD127 and CD40, macrophages showed higher levels of both
markers in as compared to BCC (Figure 2c-d). This trend was reproducible in multiple
tumors from different patients as shown by overlaid representative histograms of CD40PerCP and CD127-PerCP in SCC (red) and BCC (blue) (Figure 2c-d). Similar results was
seen in CD68+CD163+ as shown by significant shifts in histograms of arginase I (M2),
MMP9 (TAM), CD40 (M1), and CD127 (M1) (Figure 2d).

Sub-population analysis of SCC and BCC TAMs demonstrates the varied nature of
the TAM polarization state
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The multi-color nature of flow cytometry allowed us to utilize the data for subpopulation analysis. In order to enhance analysis of data, M1 versus M2 graphs were
created to help us delineate M1 and M2 activation of TAMs in SCC versus BCC. CD127
versus arginase I graphs demonstrated the following reproducible pattern as shown in
tumors from different patients: TAMs from SCC are both M1 (CD127) and M2 (arginase
I) activated. By comparison, TAMs from BCC mainly show a state of quiescence and
demonstrate lower M1 and M2 activation (Figure 4). In BCC, a quadrant plot was used to
analyze distribution of macrophage polarization. Macrophages are in a baseline state,
meaning neither M1 nor M2 activated (78.7 %), only M1 activated (7.07 %), only M2
activated (5.82 %), or express both M1 and M2 markers simultaneously (8.37 %) (Figure
4). In order to compare this polarization pattern, we carried out a similar analysis in two
SCCs. In a smaller-sized SCC, there are four distinct populations that can be appreciated
in the FACS plot: baseline state (7.85 %), M1 only (42.8 %), M2 only (5.49 %), both M1
and M2 activation (23.6 %). In a larger SCC, we delineated two populations: the majority
of macrophages are M1 and M2 activated (94.1 %) and the rest are in a baseline state
(4.02 %). This type of sub-population analysis demonstrates that TAMs are not in one
particular polarization program but rather can express M1 and M2 markers either
individually or simultaneously (Figure 4).

TAMs in SCCs are M1 & M2-activated in comparison with peri-tumoral normal
skin-resident macrophages
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Immunophenotype of tumor-associated macrophages in cutaneous SCC was
determined using flow cytometry and compared directly to tissue resident macrophages
in peri-tumoral normal skin from the same subject. Biopsy-confirmed SCCs (n=3) from
Mohs debulked tumor specimens and peri-tumoral normal skin (n=3) from the same
patient were obtained. Both specimens were digested enzymatically and processed in an
identical fashion for flow cytometric immunophenotype as previously described. The
experiment was performed a total of three times together with corresponding peri-tumoral
normal skin. The results of this experiment show that TAMs in human SCCs are M1
polarized as demonstrated by an increase in CD127 and CD40 levels as compared to peritumoral normal skin (Figure 5). In addition, TAMs are also M2 polarized (increased
arginase I) and produce increased levels of MMP-9 as compared to tissue resident
macrophages in normal skin (Figure 5).

Co-culture of human SCCs with naive THP-1 macrophages reproduces TAM
polarization in vitro
We designed an in vitro co-culture assay with human SCC and THP-1 cells to
investigate whether a paracrine, non-contact-dependent communication between TAMs
and SCC cells can account for our in vivo observation of heterogeneous M1 and M2
polarization. Biopsy-confirmed cutaneous SCC from Mohs debulked tumors was
mechanically dissociated with sterile surgical scissors and suspended in RPMI with 10 %
FCS in a 1 um Transwell cell culture insert. In the lower chamber, THP-1 macrophages
were plated at 1 million cells/mL. After 48 hours and 72 hours of co-culture, the upper
insert was removed and THP-1 macrophages were analyzed by FACS for M1, M2, and
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MMP-9 expression. For a control, we used peri-tumoral normal skin from the same
patient, which was surgically removed from an adjacent anatomical location at the same
time and co-cultured the dissociated skin with THP-1 macrophages. As a second negative
control, THP-1 macrophages were grown fresh RPMI, without any other cells plated in
co-culture. To analyze the state of polarization by FACS, we first gated live cells,
followed by gating CD68+CD45+ cells, which represented the majority of THP-1
macrophages. THP-1s were polarized to heterogeneous M1 and M2 activation through
paracrine interaction with human SCC tumor suspension (Figure 6). THP-1s displayed
characteristics of M1 and M2 activation as demonstrated by significant shifts in arginase
I, CD127 and CD40 compared to peri-tumoral normal skin and non-stimulated THP-1,
which closely correlates with our in vivo findings of immunophenotype of TAMs in
human SCCs. In addition, MMP-9 production is significantly increased through paracrine
signaling of SCC cells co-cultured with THP-1s as compared to peri-tumoral normal skin
co-culture (Figure 6). Similar results are observed after 48 hours and 72 hours of
incubation with SCCs from different patients.

Soluble factor(s) in tumor-conditioned media from SCC and BCC differentially
polarize human macrophages to a TAM phenotype
Conditioned media was prepared from dissociated SCCs (n=3) and BCCs (n=3) in
vitro. Biopsy-confirmed Mohs debulked tumor specimens were dissociated in a sterile
environment and placed in RPMI-complete for 24 hours. The tumor supernatant was
carefully aspirated and sterile filtered. THP-1 cells were incubated in the presence of
control RPMI media, SCC-conditioned media, and BCC-conditioned media for 48 hours
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in a humidified TC incubator at 37 ºC. Human macrophages demonstrate differential
activation as a result of incubation in SCC- and BCC-conditioned media (Figure 7). THP1 cells incubated in SCC-conditioned media showed significant M1 and M2 polarization
compared to either BCC or THP-1 cells control as demonstrated by significant shifts in
histograms of CD40 (M1), CD127 (M1), and arginase I (M2) (Figure 7). In addition,
MMP-9 production by THP-1 cells was strongly induced by SCC-conditioned compared
to BCC-conditioned media (Figure 7). The results conform to findings from co-culture of
THP-1 cells and SCC, and in vivo phenotype of TAMs in SCCs versus BCCs. Soluble
factor(s) present in tumor-conditioned media are sufficient to polarize THP-1 cells in
vitro towards the respective TAM phenotype we observed in vivo in SCCs and BCCs.

Imiquimod induces M1 activation of THP-1 cells in vitro as demonstrated by flow
cytometry
To determine, whether TLR-7/8-agonists were sufficient to polarize our THP-1
monocytic cell line to an M1 state, we carried out in vitro experiments with both
imiquimod and resiquimod, an investigational analogue of imiquimod. THP-1 cells were
plated in the control media or in media containing 50 µg/mL imiquimod or 10 µg/mL
resiquimod. Positive controls of the TLR-4 agonist LPS (100 ng/mL) and IFN-gamma
(20 ng/mL) were included. After 48 hours, THP-1 cells were analyzed by flow cytometry
for expression of M1 markers (CD40 and CD127). In analysis of results, live cells were
gated on based on FSC and SSC. CD68+CD45+ cells were then selected and histograms
of M1 markers were produced. Interestingly, imiquimod induced significant M1
polarization as shown by histogram shifts in CD40 and CD127 fluorescent intensity of
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macrophages compared to negative control (Figure 8). The positive control with LPS and
IFN-gamma induced the expected shift in M1 markers (Figure 8). Resiquimod (TLR-7/8
agonist) also induced M1 markers (Figure 8). Together, the results of these series of
experiments demonstrate a possible immunologic mechanism for imiquimod, which
involves amplification of M1 polarization state of macrophages.

Imiquimod treatment leads to M1 polarization of TAMs in SCC in vivo
We obtained a fresh SCC specimen from a patient treated for 2 weeks with topical
2.5 % imiquimod treatment to scalp tumor. A comparable SCC was utilized as control.
Both tumors were processed in parallel for flow cytometric analysis. In vivo
immunophenotype of CD68+CD45+ macrophages was determined with FACS. In
agreement with in vitro experiments, imiquimod treatment polarized TAMs to an M1
activation state (Figure 9). We observed significant induction of CD40 by imiquimod as
shown in Figure 9, with a majority of macrophages M1 polarized (94.5 %) in contrast to
control SCC TAMs that were 45.8 % M1 polarized. Coordinately, there was also a
positive shift in another M1 marker, CD127 (Figure 9). Interestingly, imiquimod
treatment leads to down-regulation of the tumor promoting metalloproteinase, MMP-9 by
TAMs (Figure 9). Arginase I levels did not show an observable shift in this case (Figure
9). In summary, imiquimod treatment leads to M1 activation of TAMs and downregulation of MMP-9.

Imiquimod is a dual immunomodulator of TAMs in vitro through M1 activation and
M2 inhibition
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We attempted to investigate whether imiquimod plays an immunomodulatory role
for TAMs in the tumor microenvironment. To answer this question, we devised an
experiment that models the tumor microenvironment. Briefly, THP-1 cells were plated in
tumor-conditioned media from either SCC or BCC. The conditioned media was prepared
from fresh Mohs debulked tumor specimens that were mechanically dissociated and
placed in RPMI-complete for 24 hours, followed by sterile filtration with 0.45 µm filter
and freezing at -80 ºC. THP-1 cells were plated in either BCC- or SCC-conditioned
media in the presence or absence of 50 µg/mL imiquimod. After 48 hours of incubation,
THP-1 cells were analyzed by flow cytometry for M1 (CD127), M2 (arginase I) and
MMP-9. THP-1 cells stimulated by SCC supernatant alone were M1 and M2 activated as
seen by upregulation of MMP-9, arginase I, CD127, and CD40. Stimulation by BCC
supernatant alone also causes M1 and M2 activation though to a lesser degree. The levels
of M1 and M2 markers, in contrast, are significantly modulated by presence of
imiquimod in tumor supernatants. The results of this experiment indicate that imiquimod
plays an immunomodulatory role by up-regulating M1 polarization, while simultaneously
down-regulating arginase I (M2) and MMP-9 production as seen in THP-1s exposed to
BCC supernatant with imiquimod as compared to BCC supernatant without imiquimod
(Figure 10). The arrows on the histograms indicate the direction of skewing induced by
imiquimod (Figure 10). A similar pattern is observed in another experiment with THP-1
cells incubated in SCC-conditioned media in presence and absence of imiquimod (Figure
10). In conclusion, imiquimod lead to significant M1 activation and down-regulation of
M2 polarization and MMP-9 production in macrophages primed in tumor-conditioned
media (Figure 10).
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Imiquimod-treated THP-1 cells induce apoptosis in human epidermoid carcinoma
cells
In order to determine whether imiquimod can activate anti-tumoral capacity of
macrophages, we designed an experiment using THP-1 cells and A431 epidermoid
carcinoma cells. THP-1 cells were first primed by imiquimod or control media for 48
hours and then cells were washed. The resulting control and imiquimod-primed THP-1
cells were then utilized in a co-culture system with epidermoid carcinoma cells. The
tumor cells were plated and control and imiquimod pre-treated THP-1 cells were placed
in the upper Transwell insert. After 72 hours of incubation, we measured level of
apoptosis in epidermoid carcinoma cells using Annexin FITC kit (eBioscience) and
propidium iodide. This experimental setup is a non-contact-dependent system that allows
exchange of soluble factors from THP-1 cells to tumor cells.
The level of apoptosis in tumor cells exposed to control THP-1 cells and
imiquimod-primed THP-1 cells is shown in Figure 11. The graph shows propidium
iodide-PerCP versus Annexin V- FITC staining (Figure 11). Early apoptosis was
measured by determining the percentage of Annexin V-positive cells, which are negative
for propidium iodide. The rate of early apoptosis was 12.2 % in the imiquimod group as
compared to 8.47 % in control group (Figure 11). This demonstrates that imiquimod
priming the THP-1 cells resulted in a higher level of early apoptosis of epidermoid
carcinoma cells compared to naive THP-1 cells. Late apoptosis was measured as
percentage of double positive cells for Annexin V-FITC and propidium Iodide-PerCP
(Figure 11). Interestingly, level of late apoptosis was 6.16 % in the tumors cells co-
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cultured with imiquimod primed macrophages as compared to 1.04 % in the tumor cells
co-cultured with naive macrophages (Figure 11). These findings reveal a six-fold increase
in the level of late apoptosis of tumor cells in the imiquimod-primed group as compared
to the control group.
THP-1 cells primed with imiquimod phagocytose significantly more tumor cells
compared to naive THP-1 cells
To whether imiquimod induces macrophage phagocytosis of tumor cells, we
devised a phagocytosis assay using PE-labeled tumor cells and human macrophages
primed with imiquimod. First, THP-1 cells were incubated in media with and without
imiquimod for 48 hours. The THP-1 cells were then washed and used for tumor cell
phagocytosis experiments. A431 epidermoid carcinoma cells were labeled with PE dye
using PKH26 kit (Sigma Aldrich). The cell membrane PE labeling allows the
phagocytized cells to be quantified using flow cytometry. PE-labeled epidermoid
carcinoma cell were mixed with control or imiquimod-primed THP-1 cells in a ratio of
6:1 to mimic the in vivo tumor microenvironment. The samples were then incubated in a
shaking TC incubator for 1 hour at 200 rpm. Samples were then prepared for flow
cytometric analysis using CD45 APC.
The level of phagocytosis was determined by measuring the percentage of PEpositive, CD45+ macrophages (Figure 12). Interestingly, the rate of phagocytosis was
68.2 % in the imiquimod-primed macrophages as compared to 8.22 % in the control
naive macrophages (Figure 12). The cell-free negative control had a background level of
0.27 % positive staining as expected (Figure 12). These findings demonstrate that
imiquimod induces macrophages to phagocytose epidermoid carcinoma cells.
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DISCUSSION
TAMs in cutaneous SCCs have higher levels of both M1 and M2 polarization than
those TAMs in BCCs
We hypothesized that TAMs from SCC had a different level of activation than
those from BCCs given their markedly different clinical features. To test this, we
isolated tumor associated macrophages from SCCs and BCCs in vivo and characterized
them with multiple panels utilizing florescent active cell sorting (FACS). FACS
experiments on cutaneous neoplasms have been historically challenging due to technical
difficulty of digestion of such highly collagenous tumors while preserving cell viability.
This study presents a technical advance in the field by providing a simple, reproducible
technique for creating a viable cell suspension of SCCs and BCCs that is suitable for flow
cytometric analysis of the wide variety of cell types that make up these skin tumors. The
FACS immunophenotype panel of TAMs in cutaneous SCCs demonstrates that
macrophages have a heterogeneous activation state characterized by both M1 and M2
activation (Figure 2). Based on our flow cytometric immunophenotypes from multiple
tumors (n=14), all from different patients, TAMs are consistently activated with profiles
unique to SCCs versus BCCs, with SCCs demonstrating higher M1 and M2 activation
(Figure 2). Our findings are in agreement with recent findings of M1 and M2 gene
expression profile of TAMs in SCC (24). The authors show that TAMs in SCC are
heterogeneously activated, exhibiting both M1 and M2 states of activation, and that
macrophages can simultaneously express genes commonly associated with Th1 and Th2
responses (24). To further investigate TAM phenotypes in vivo, we obtained SCCs
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tumors (n=3) and peri-tumoral normal skin samples (n=3) from the same patients. This
served a control for TAMS as tissue resident macrophages can have varied phenotypic
characteristics depending on their tissue niche. Dermal macrophages from the same
patient are the ideal control for immunophenotype characterization of TAMs in vivo in
human SCCs. The results demonstrate that TAMs in SCCs are M1 and M2 activated and
also express high MMP-9 levels compared to skin-resident macrophages (Figure 5).
The simple categorization of macrophages into M1 and M2 phenotypes does not
capture the observed complexity of TAM activation in SCC microenvironment.
Therefore, a revised model of macrophage activation states taking into account the shades
and overlaps of activations states known as the color wheel of macrophage activation is
more appropriate in explaining the in vivo behavior of macrophages (20, 32). In this
model, macrophages are divided into three populations: classically activated
macrophages, wound-healing macrophages, and immune regulatory ones, while allowing
for overlap of these three states on a color wheel (20, 32). The phenotypic complexity of
TAMs is possibly due to heterogeneity of the tumor microenvironment ranging from
hypoxic and necrotic regions to more vascularized regions; In addition, infiltration by a
variety of T cells, IFN-gamma producing Th1, IL-4 and IL-13 producing Th2 cells and
IL-10 producing T-reg cells results in a heterogeneous cytokine milieu in the tumor
microenvironment. In support of this hypothesis, it has been shown that SCC is
associated with a mixed Th1 and Th2 gene expression profile (33). In addition, It is
important to note that the monocyte lineage, the precursor to TAMs and tissue-resident
macrophages, are themselves heterogeneous, yet providing another potential factor that
mediates the diverse phenotypic characteristic of TAMs (34). In addition, tumor cells in
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SCC and BCC can produce cytokines such as IL-10 further contributing to the diverse
nature of chemical messages in the tumor niche (35).

Higher MMP-9 and arginase I Expression in TAMs in SCCs versus BCCs
MMPs are a family of zinc-dependent neutral endopeptidases that can break down
the components of the extracellular matrix (ECM) (36). MMPs play an active role in
many aspects of tumor development including angiogenesis, local tissue invasion, and
metastasis (37). The ECM is a net of connective tissue that stands in the way of tumor
growth and invasion. When tumor cells are embedded in this rigid, spheroid matrix,
tumor proliferation is suspended (38). In addition to tumor proliferation, MMPs allow
tumor cells to locally invade and metastasize through vascular and lymphatic pathways
through breakdown of basement membrane proteins (39, 40). Macrophages are known to
produce matrix metalloproteinase, primarily MMP-9 and MMP-2 and can contribute to
tumor growth, invasion and metastasis by supplying this pivotal factor in the tumor
microenvironment (22, 23).
Increased expression of MMP-9 in TAMs from SCCs as compared with BCCs is
an interesting finding that suggests a possible reason for the difference in clinical
behavior between SCC and BCC (Figure 2). MMP-9 supplied by bone marrow-derived
cells has been shown to be involved in skin carcinogenesis (41). A murine model of
HPV16-induced de novo SCC demonstrated that MMP-9 knock out mice have reduced
keratinocyte proliferation and delayed progression from hyperplasia to dysplasia and
finally to invasive carcinoma (41). In a similar manner, immunohistochemical studies of
MMP-9 and collagen IV, one of the known substrates of MMP-9, revealed that SCC has
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increased expression of MMP-9 and MMP-2 and decreased collagen IV when compared
to BCC (42). Given this essential role of MMP-9 in skin carcinogenesis, increased MMP9 produced by TAMs in SCC versus BCC can partly explain the clinical behavior of
these two tumor types.
Arginase I is a key enzyme that is involved in polyamine production (putrescine,
spermine, spermidine). Arginase I converts Arginine to Ornithine, which is subsequently
converted to putrescine by Ornithine Decarboxylase (ODC). Putrescine is then
interconverted to other polyamines through the actions of spermidine synthase and
spermine synthase (43). This biochemical pathway leads to production of polyamines in
the tumor niche, which can then be utilized by tumor cells for cellular proliferation and
growth (44). The distinctly higher levels of arginase I in TAMs from SCCs versus BCCs
may be a pathophysiologic reason for the higher growth rates observed in SCC as
compared to BCC (Figure 2). Finally, higher expression of arginase I in TAMs from
SCCs also demonstrates that there are more M2, tumor-promoting macrophages present
in SCCs as compared to BCCs.

Soluble factors are sufficient to reproduce the TAM immunophenotype
Co-culture of human cutaneous SCC with THP-1 cells demonstrated that cells in
the tumor microenvironment are able to induce M1 and M2 polarization in macrophages
in vitro through non-contact-dependent, paracrine communication (Figure 6). The fact
that normal skin from the same patient does not induce the phenotype demonstrates that
the soluble factor(s) are present in the tumor and absent from adjacent “normal” tissue.
This is similar to our in vivo FACS immunophenotype of TAMs in SCCs, which shows
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heterogeneous M1 and M2 activation and increased MMP-9 production as compared to
peri-tumoral normal skin and BCC (Figure 2 and 5). Increased MMP-9 production in
THP-1 cells as a result of co-culture with SCCs is also consistent with our in vivo results
of TAMs in SCCs.
The possible mechanism of TAM immunophenotype induction is through soluble
factor(s) that are responsible for induction of TAM immunophenotype (Figure 7). The
source of such signaling factors can include tumor cells, Th1 and Th2 cells, other
immune cells, fibroblasts, and variety of other cells in the tumor microenvironment. In
support of this hypothesis, we demonstrated that THP-1 cells could be induced to their
respective M1-M2 phenotype in vitro using filtered (cell-free) tumor-conditioned media
from SCCs and BCCs (Figure 7). The results show a stepwise increase in mean florescent
intensity from THP-1 cells incubated with control media to the BCC-conditioned media
to the SCC-conditioned media (Figure 7). In summary, the results of both SCC and peritumoral normal skin co-culture with THP-1 cells together with in vitro THP-1 cell
polarization with SCC-conditioned and BCC-conditioned media further support the in
vivo FACS immunophenotype of TAMs isolated from NMSC (Figure 2, 6, and 7). Given
the heterogeneity and complexity of the tumor niche, monocytes recruited into the tumor
microenvironment are exposed to a multitude of factors. Based on our findings, the
heterogeneous, multi-focal activation is most likely the result of multiple soluble factors
that act through a paracrine, non-contact-dependent relationship to induce an intricate
phenotype in TAMs that involves features of both M1 and M2 activation.
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Imiquimod induces M1 activation of TAMs in vivo and in vitro
TAMs have been described as as a double-edged sword in cancer biology (45). It
is important to understand their multifaceted behavior in order to devise ways to alter
their activation state as a therapy for cancer. It is known that TAMs are dynamic and can
be polarized into different activation states through exposure to different cytokines and
immunomodulators (21, 23, 46). Given the broad role of TAMs in a variety of
malignancies, it is conceivable that macrophage-targeted therapies will be useful for
numerous cancers. Both imiquimod and resiquimod have been shown to be
immunomodulators of T cells through the enhancement of Th1 cells and IFN-gamma
production (47). Clinically, treatment of superficial BCC with 5 % imiquimod leads to
significant increase in infiltrating CD68+ macrophages compared to baseline (48).
Similarly, treatment of actinic keratoses (AK) with imiquimod leads to increase in gene
expression of macrophage markers (CD163, CD14, CLECSF9) and activated T cells
including cytotoxic T cells and Th1 cells (49). The increased infiltration of macrophages
into BCCs and AKs after treatment with imiquimod has significant implications in terms
of the mechanism of imiquimod's tumoricidal action. We analyzed published microarray
data of up-regulated genes in BCCs (n=36) after topical imiquimod therapy. Ten known
M1 genes are up-regulated through imiquimod treatment including CD40, CCR7, CD86,
STAT1, MX-1, CXCL9, CXCL10, CCL2, CCL3, and CCL4 (Supplementary Figure 1)
(50).
We sought to determine the state of polarization of TAMs in vivo in response to
imiquimod treatment using flow cytometric immunophenotyping of SCCs as compared to
SCC controls. We found that imiquimod treatment of SCCs leads to strong M1 activation
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of TAMs as shown by increased levels of CD40 and CD127 as compared to control SCCs
(Figure 9). Similarly, in vitro stimulation of THP-1 cells with imiquimod and resiquimod
induced M1 activation as well (Figure 8). From a mechanistic viewpoint, M1
macrophages are known to have potent tumoricidal properties mediated by production of
pro-inflammatory factors (51). Given that Th1 cell are induced by imiquimod, one of the
contributors to M1 polarization of macrophages by imiquimod is possibly through Th1
production of IFN-gamma (21). Interestingly, using imiquimod alone, we showed that
strong M1 activation could be reproduced with human monocytic cell lines in the absence
of T cells and other cytokines (Figure 8). Therefore, imiquimod and resiquimod are
sufficient to attenuate macrophage polarization without the need of adaptive immune
cells. Imiquimod is known to be a TLR-7/8 agonist and this maybe the mechanism of
M1 polarization that we have observed in vivo and in vitro (52).

Imiquimod is an immunomodulator of macrophages
The results in Figure 10 provide insight into a novel mechanism of imiquimod’s
action that we subsequently studied further using in vitro experiments to model the tumor
microenvironment. We obtained tumor-conditioned media through manual dissociation
of Mohs debulked tumors incubated in complete media for 24 hours and which we then
filtered in a sterile fashion. Next, we polarized THP-1 cells in presence or absence of
imiquimod to study effects on macrophage polarization. Imiquimod leads to strong M1
polarization and simultaneous reduction in both M2 polarization and MMP-9 production
(Figure 10). These findings imply that under conditions that model the microenvironment
of BCCs and SCCs, imiquimod can override these states of TAM polarization, resulting
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in a high M1 and low M2 polarized state. This modulated state of polarization is
markedly distinct from the TAM immunophenotype that we have shown in vivo and in
vitro and provides insight to a potential mechanism of imiquimod. The other implication
is that TAMs in human tumors exhibit plasticity and can be modulated through both
amplification of their tumoricidal effects and attenuation of their tumor-promoting
functions. TAMs provide a continual supply of growth factors, angiogenic factors and
MMPs that contribute to growth, invasion, and metastasis of tumor cells (3, 53).
Macrophage immunomodulators may be useful across a variety of tumor types as TAMs
are present in numerous types of tumors.

Imiquimod-primed macrophages induce apoptosis of tumor cells and demonstrate
enhanced phagocytosis of epidermoid carcinoma cells
We asked question of whether imiquimod can induce macrophage to display
tumoricidal activity. We specifically focused on apoptosis of tumor cells and
phagocytosis of tumor cells by macrophages. In our apoptosis experiments, imiquimodprimed macrophages induced apoptosis of epidermoid carcinoma cells at a level six-fold
greater than naïve macrophages (Figure 11). This was carried out in a non-contact
dependent co-culture system. The results demonstrate that imiquimod can induce
macrophages to exhibit tumoricidal activity through the secretion of soluble cytotoxic
factors that can cause both early and late apoptosis in carcinoma cells (Figure 11). Given
that M1 macrophages are known for their pro-inflammatory activity against infectious
agents, we speculate that imiquimod causes macrophages to polarize to an M1, proinflammatory state, which results in the secretion of cytotoxic factors such as tumor
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necrosis factor (TNF), Nitric Oxide (NO), and reactive oxygen species leading to
increased apoptosis of tumor cells (51).
We devised a phagocytosis assay utilizing PE-labeled epidermoid carcinoma cells
and THP-1 macrophages primed with imiquimod to investigate whether imiquimod
enhances the phagocytic activity of macrophages. In a contact system, tumor cells labeled
with PE were incubated in suspension with control and imiquimod primed macrophages.
Interestingly, imiquimod primed macrophages had significantly enhanced phagocytic
activity. The rate of phagocytosis of PE-labeled tumor cells was 68.2 % in the imiquimod
primed macrophage group compared to 8.22 % in the control macrophage group (Figure
12). The results of these experiments demonstrate that imiquimod can activate
tumoricidal activity of macrophages as shown by both enhanced apoptosis and
phagocytosis of tumor cells by imiquimod-activated macrophages.
In conclusion, using a novel method of FACS immunophenotyping of SCC and
BCC tumor cells, we have shown that TAMs in human cutaneous SCCs show a
heterogeneous M1 and M2 activation state. TAMs in SCCs express significantly higher
levels of M1 (CD40, CD127) and M2 (arginase I) markers as compared to BCCs and also
express higher levels of MMP-9, a pivotal factor in ECM remodeling and tumor invasion
(36, 38, 39). SCC, a relatively aggressive human skin cancer, is able to induce a more
highly polarized TAM population, which is capable of both tumor-promoting functions
(M2, MMP-9) and tumor-inhibiting functions (M1) in vivid contrast to the more indolent
skin cancer, BCC. These findings demonstrate that TAMs may play an important role in
pathophysiology of NMSC, the most common cancers in humans. Future studies include
the characterization of how the M1/M2 heterogeneity of TAMs is maintained in the
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tumor microenvironment and also in the identification of soluble macrophage
modulators.
Further, we demonstrated that imiquimod, a TLR-7 agonist approved by the FDA
for the treatment of superficial BCC, is able to induce M1 polarization in TAMs from
human SCC and can induce the same phenotype in vitro. Further, imiquimod directly
induces M1 polarization and suppresses M2 polarization in a tumor microenvironment
assay. In functional assay, we demonstrated that activates macrophages to both induce
apoptosis and phagocytosis of carcinoma cells.
Taken together, these results suggest a mechanism by which imiquimod activates
TAMs to an M1 polarized state capable of induction of apoptosis and phagocytosis of
tumor cells. These results reveal a novel immunologic mechanism for imiquimod in the
treatment of skin cancer and suggest that modulation of TAM immunophenotype may be
a therapeutic strategy useful in the treatment of numerous cancers.
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Table A - Characteristic of Subjects and tumor specimens

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Type

Age

BCC
SCC
SCC
SCC
BCC, Micronodular
SCC
BCC
BCC
BCC, nodular and infiltrating
SCC
SCC, Invasive SCC to base
SCC
SCC
SCC
SCC
BCC- to base
SCC
SCC, Peri-tumoral skin
SCC
SCC
BCC with infiltrative features
SCC
BCC
SCC
SCC, Peri-tumoral skin

54
58
100
98
71
95
78
77
76
49
85
81
96
65
51
66
78
83
85
92
63
83
87
91
67

Gender Duration
of lesion
M
2 years
M
6 months
M
6 months
F
3 months
M
2 years
F
3 months
M
6 months
M
1 year
M
6 months
M
6 months
M
3 months
M
6 months
F
6 months
M
3 months
M
6 months
M
6 months
M
1 month
M
2 months
M
3 months
F
3 months
M
10 years
F
3 months
F
5 years
F
1 year
M
6 months

Tumor size (cm)

Location

Skin CA history

1.8 x 1.8
1.2 x 1.2
2.5 x 2.5
2.0 x 2.5
0.4 x 0.5
2.0 x 1.8
1.2 x 1.0
1.5 x 1.1
1.0 x 1.2
0.8 x 0.9
0.9 x 0.8
1.0 x 1.2
1.8 x 2.3
1.3 x 1.4
1.3 x 0.9, 1.0 x 1.5
0.7 x 0.7
1.3 x 1.3
2.6 x 3.4
1.3 x 1.4
2.0 x 2.0
3.5 x 2.4
0.8 x 0.8
3.0 x 3.0
1.0 x 1.0
2.5 x 2.4

L to midline mid back
L temple
L radial hand
L cheek
L forehead
R nasal bulb
L inferior eyelid
L side of nose
L zygoma
L cheek
L ear
R inferior cheek
R medial cheek
Frontal Scalp
L preauricular, L Scalp
R nose
L forehead
R cheek
R distal shin
L mid anterior leg
L chest
L cheek
Back
R lower cheek
R temple

none
Infitrative BCC, SCC, BCCs
BCC, SCC
SCC
none
SCC
none
BCC, SCCis, malignant melanoma
BCC
SCCis, Aks, SCC, BCC
none
BCC
none
SCC, BCC
Invasive SCCs, Aks
none
none
SCC
AK, BCC
AK
none
none
none
SCCis, Atypical nevus
none

Abbreviations: M- Male, F- Female, L- Left, R- Right, SCC- Squamous Cell Carcinoma, BCC- Basal Cell
Carcinoma, SCCis- Squamous cell carcinoma-in situ, AK- Actinic Keratosis
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Figure 1 Higher density of CD68+ tumor-associated macrophages are found in cutaneous SCC as
compared to BCC
(a) BCCs (n=6) and SCCs (n=5) were stained with CD68 antibody, a marker of tumor-associated
macrophages (TAMs) and visualized at 40X.
(b) Number of CD68+ TAMs was counted in six high power fields (HPF) for each BCC and SCC using
Optiphot Nikon microscope with camera. Number of TAMs per HPF in SCC is significantly higher than
BCC as shown in this graph (* p-value < 0.0001, unpaired t test)
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Figure 2 Tumor-associated macrophages in SCC and BCC show differential activation based on flow
cytometric immunophenotype of M1 and M2 markers
(a) SCCs (n=7) and BCCs (n=7) excised using Mohs were enzymatically dissociated with Liberase for flow
cytometric immunophenotyping. CD68-PE and CD45-APC were utilized as macrophage marker and
common leukocyte marker respectively. As seen on this FACS plot, CD68+CD45+ population was gated
upon as TAMs. CD68-CD45+ were gated upon to represent other white blood cells (other WBCs). The
CD68-CD45- population seen in these plots represents tumor cells and other non-hematopoietic cell types
in the tumor microenvironment.
(b) Histograms of MMP-9 and arginase I were created for TAMs (CD68+CD45+), shown in black, and
other WBCs (CD68+CD45-), shown in grey. The resulting overlayed histograms show that MMP-9 and
arginase-I have higher levels in TAMs as compared to other WBCs.
(c) CD68+CD45+ TAMs in SCC and BCC were gated upon. Histograms of arginase-I, MMP-9, CD40, and
CD127 were created and overlayed for comparison of TAM immunophenotype in SCC (red) vs. BCC
(blue). Characterization of M1, pro-inflammatory surface markers shows that TAMs in SCC have higher
levels of CD40 and CD127 compared to BCC. Characterization of MMP-9 and Arginase-I, which are
markers of tumor-promoting TAMs, shows that TAMs in SCC microenvironment have higher levels of both
markers as shown by noticeable histogram shifts in these plots.
(d) CD163+CD68+ TAMs in SCC have higher levels of M1 (CD40, CD127), arginase I, and MMP-9 as
compared to CD163+CD68+ TAMs in BCC as shown by histogram shifts.

Mean Microarray signal

Figure 3 Microarray of Human SCC and BCC shows differential expression of CD68, MMP-9, and
arginase-I
Whole tumor microarrays of human SCCs (n=13) and BCCs (n=11) and normal skin (n=4) from published
data were utilized to calculated microarray signal density for MMP9, CD68, and arginase-I. MMP-9
expression is higher in SCC compared to BCC, which are both higher than normal skin. Similarly, CD68, a
classic macrophage marker shows higher levels of expression in SCC compared to BCC and normal skin.
Arginase I shows high expression in SCC, but no expression in BCC or normal skin. % arginase I positive
is defined as percentage of all samples with significant p-values indicating that the gene expression is
present in microarray profile of the tumor. SCC shows 36.36 % of arginase I positivity whereas BCC and
normal skin demonstrate 0 % arginase I positivity.
Abbreviations: Arg-I (arginase I)
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Figure 4 Subpopulation analysis of SCC and BCC tumor-associated macrophages demonstrates
heterogeneous states of macrophage polarization
M1 vs. M2 graphs were created for CD68+CD45+ cells using CD127 (M1) vs. arginase-1 (M2) plots. In
BCC, 78.7 % of TAMs have baseline level of activation (78.7 %), M1 only activation (7.07 %), M2 only
activation (5.82 %), and M1-M2 activation (8.37 %). In contrast, in a small SCC, 7.85 % of TAMs have
baseline activation (7.85 %), 42.8 % M1 only (42.8 %), M2 only (5.49 %), and M1-M2 activation (23.6
%). In large SCC, majority of TAMs have M1-M2 activation (94.1 %) and a small percentage have
baseline activation (4.02 %). The results suggest that TAMs in SCC have heterogeneous M1-M2
immunophenotype compared to BCC. In BCC, majority of TAMs are quiescent whereas in SCC most
TAMs have a heterogeneous state of polarization.

100

60

40

80

80

60

60

60

40

20

20

0

80

% of Max

SCC	
  

Control	
  

% of Max

% of Max

80

0

100

101

102
FL1-H: CFS

103

Arginase	
  I	
  (M2)	
  

104

100

100

100

101

102
FL1-H: CFS

103

104

MMP-‐9	
  

% of Max

100

40

40

20

20

0

0
100

101

102
FL3-H: PerCP

CD127	
  (M1)	
  

103

104

100

101

102
FL3-H: PerCP

103

CD40	
  (M1)	
  

TAMs	
  in	
  SCC	
  
Control:	
  Macrophages	
  from	
  adjacent	
  normal	
  skin	
  (same	
  subject)	
  

Figure 5 TAMs in cutaneous SCC are heterogeneously activated in comparison with peri-tumoral
skin-resident macrophages
SCCs (n=3) and peri-turmoal normal skin (n=3) were used to compare CD68+CD45+ immunophenotype of
TAMs as compared to skin-resident tissue macrophages. SCC from Mohs and the peri-tumoral normal skin
from the same patient were used in each experiment. Tumors and peri-tumoral skin were digested using
Liberase and prepared for flow cytometry. CD68+CD45+ cells were gated upon and histograms of arginaseI (M2), MMP-9, CD127 (M1), and CD40 (M1) were created for both SCC and peri-tumoral normal skin.
The results shows that TAMs in SCC (red) have higher levels CD127, CD40, MMP9, and arginase I as
compared to tissue-resident macrophages in peri-tumoral normal skin (grey).
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Figure 6 Co-Culture of Human SCC with Human monocytes (THP-1) leads to TAM programming
characterized by M1 and M2 activation compared to peri-turmoal normal skin
SCC and peri-tumoral normal skin from the same patient were obtained from Mohs surgery. Tumor and peritumoral skin were manually minced and plated in RPMI complete in BD falcon culture insert with 1 µm PET
membrane and transferred to six-well plate containing 1 million THP-1 cells in RPMI complete. After 72 hours,
THP-1 cells were stained for FACS Immunophenotype (M1, M2, and MMP-9). CD68+ CD45+ cells were gated
upon, and histograms representatives of arginase I, CD127, CD40 and MMP-9 are shown above. THP-1 cells cocultured with SCC tumor cells have higher levels of M1 markers (CD40, CD127), M2 markers (arginase I), and
MMP-9 compared to BCC and normal skin.
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Figure 7 Polarization of THP-1s with SCC (red) and BCC (blue) conditioned media demonstrates distinct
degrees of M1 and M2 activation
SCCs (n=3) and BCCs (n=3) tumors from MOHS were minced and placed in RPMI complete media in 37 ºC tissue
culture incubator for 24 hours. The supernatants were then sterile-filtered. THP-1 cells were incubated in control
RPMI, SCC-conditioned RPMI and BCC-conditioned RPMI. THP-1s were then analyzed using flow cytometry for
CD40, CD127, arginase I, and MMP-9. THP-1 cells (red) incubated in presence of SCC-conditioned media have
higher levels of M1 markers (CD40 and CD127), M2 marker (arginase I), and MMP-9 compared to THP-1 cells
(blue) exposed to BCC-conditioned media. Control THP-1 cells are shown in grey and demonstrate baseline
expression of these markers.

Control	
  

CD40	
  (M1)	
  

Imiquimod	
  

Resiquimod	
  

LPS	
  +	
  IFN-‐gamma	
  
(PosiEve	
  control)	
  

CD127	
  (M1)	
  

Figure 8 Imiquimod (50 ug/mL) and resiquimod (10 ug/mL) induce M1 activation of macrophages in vitro
THP-1 cells were plated and the following media were used for incubation: Control RPMI media (negative
control), 50 µg/mL imiquimod in RPMI, 10 µg/mL resiquimod in RPMI, and 100 ng/mL lipopolysaccharide (LPS)
and 20 ng/mL Interferon-gamma (positive control). After 48 hours, THP-1 cells were analyzed using flow
cytometry for M1 markers (CD40 and CD127). CD68+CD45+ cells were gated upon and histograms of M1
markers were produced. Imiquimod and resiquimod induce marked M1 activation of THP-1 cells in vitro as shown
by histogram shifts compared to negative control. The positive control of LPS and Interferon-gamma shows M1
activation as expected.

Figure 9 Imiquimod treatment of SCC in vivo induces M1 activation of tumor-associated macrophages
SCC from scalp of a patient treated with topical imiquimod (2.5 %) for 2 weeks was excised with Mohs and processed
for flow cytometric immunophenotyping of TAMs. A similar SCC was used as control. CD68+CD45+ TAMs were
gated upon and histograms of M1, M2, and MMP-9 were generated. 94.5 % of TAMs in imiquimod-treated SCC have
M1 activation (CD40+) compared to 45.8 % of TAMs in control SCC. There is down-regulation of MMP-9 and no
changes in arginase-I in TAMs from imiquimod-treated SCC compared to TAMs from control SCC.
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Figure 10 Imiquimod leads to immunomodulation of macrophages towards M1 and away from M2 in the
presence of SCC- and BCC-conditioned media
Tumor-conditioned media from SCC and BCC was prepared through mechanical dissociation of tumors and
incubation for 24 hours in RPMI complete. The media was then sterile-filtered with 0.45 µm filter. THP-1 cells
were plated in BCC or SCC-conditioned medias in the presence of 50 µg/mL imiquimod or absence of imiquimod
as the negative control. After 48 hours of incubation, THP-1 cells were prepared for flow cytometry of M1 and
M2 markers, and MMP-9. In both THP-1 cells exposed to SCC-conditioned media and BCC-conditioned media,
imiquimod leads to up-regulation of M1 markers (CD40 and CD127) and down-regulation of M2 marker
(arginase I) and MMP-9. The arrows indicated the direction of immunomodulation in each graph. Therefore,
imiquimod can acts as an immunomodulator of macrophages in presence of tumor-conditioned media.

	
  

THP-‐1	
  control	
  co-‐culture	
  with	
  A431	
  

Imiquimod-‐primed	
  THP-‐1	
  co-‐culture	
  with	
  A431	
  

Propidium	
  Iodide	
  

Late	
  Apoptosis	
  

Late	
  Apoptosis	
  

Early	
  Apoptosis	
  

Early	
  Apoptosis	
  

Annexin	
  V-‐FITC	
  

6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0

THP-1 Control
THP-1 Imiquimod 50 µg/mL
72	
  hr	
  Eme	
  point	
  

THP-1 Control

THP-1 Imiquimod 50 µg/mL

Figure 11 Imiquimod-treated THP-1 cells induce enhanced apoptosis of human epidermoid carcinoma
cells in a co-culture system
THP-1s were stimulated with 50 µg/mL imiquimod in RPMI complete and control RPMI complete for 48
hours. The supernatant was then aspirated carefully and the THP-1 cells were washed twice in cold PBS.
A431 epidermoid carcinoma cells were plated in a six-well plate. THP-1 cells were placed in the upper
Transwell insert. After 3 days of incubation, the level of apoptosis in the A431 epidermoid carcinoma cells was
quantified using Annexin FITC and propidium iodide. The rate of early apoptosis (Annexin V+ Propidium
Iodide -) is 8.47 % in control group and 12.2 % in the imiquimod group. The rate of late apoptosis (Annexin V
+ Propidium Iodide +) is 1.04 % in the control group and 6.01 % in the imiquimod group. The results suggest
that imiquimod can enhance tumoricidal capacity of macrophage in a non-contact-dependent system as shown
by increased levels of early and late apoptosis in human epidermoid carcinoma cells.
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Figure 12 THP-1 cells primed with imiquimod phagocytose significantly more epidermoid
carcinoma cells (A431) compared to control THP-1 cells
THP-1 cells were stimulated with 50 µg/mL imiquimod or control media for 48 hours. At the end of
incubation, the media was aspirated and cells were wash twice in cold PBS. A431 epidermoid
carcinoma cells were labeled with PE dye using PKH26 (Sigma Aldrich). Next, the control and
imiquimod-primed THP-1 cells were mixed with A431 carcinoma cells in a ratio of 6:1 in conical
tubes. The samples were then placed in a shaking incubator at 37 ºC for 1 hour at 200 rotations per
minute. The samples were prepared for FACS using CD45 APC. CD45+ Cells were then gated upon to
distinguish THP-1 cells from tumor cells. The rate of phagocytosis was determined by gating on
CD45+ PE+ cells, which indicate marcophages that have phagocytosed PE-labeled tumor cells. The PE
histogram of THP-1 cells in imiquimod group (red) shows significant shift compared to control group.
Only 0.27 % of CD45+ THP-1 cells are positive for PE in the negative control without any tumor cells
added. The rate of phagocytosis is 68.2 % in imiquimod-primed THP-1 cells as compared to 8.22 % in
control THP-1 cells. These results suggest that imiquimod can enhanced the phagocytic capacity of
macrophages for epidermoid carcinoma cells.
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Supplementary Figure 1- 10 known M1 genes are up-regulated by imiquimod treatment of
BCC in a placebo-controlled study

